Irinotecan and bevacizumab in recurrent glioblastoma multiforme

Bibliography

• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ, Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17(8):2572-8
   PubMed Web of Science ®Google Scholar
• Lamborn KR, Yung WKA, Chang SM, Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10(2):162-70
   PubMed Web of Science ®Google Scholar
• Jain RK, di Tomaso E, Duda DG, Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8(8):610-22
   PubMed Web of Science ®Google Scholar
• Chaudhry IH, O'Donovan DG, Brenchley PE, Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001;39(4):409-15
   PubMed Web of Science ®Google Scholar
• Zhou YH, Tan F, Hess KR, Yung WKA. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003;9(9):3369-75
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-9
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002;56(2):183-8
   PubMed Web of Science ®Google Scholar
• Friedman HS, Petros WP, Friedman AH, Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17(5):1516-25
   PubMed Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K, Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75(1):156-63
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Desjardins A, Vredenburgh JJ, Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12(12):1300-10
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M, Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 2009;48(1):52-8
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape K. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol 2009;27(15S):2011
   Google Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-5
   PubMed Web of Science ®Google Scholar
• CABARET trial. Available from: http://www.australiancancertrials.gov.au/search-clinical-trials/search-results/clinical-trials-details.aspx?TrialID=335731&ds=1
   Google Scholar
• BELOB trial. Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1929
   Google Scholar
• Norden AD, Drappatz J, Muzikansky A, An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009;92(2):149-55
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm S, Chamberlain MC, A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010;116(22):5297-305
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Lassen U, Hansen S, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010;12(5):508-16
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83(5):588-93
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27(12):2052-8
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ, Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 2010;96(2):219-30
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28(7):1168-74
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27(8):1268-74
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Chang SM, A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81(3):271-7
   PubMed Web of Science ®Google Scholar
• Marx GM, Pavlakis N, McCowatt S, Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2001;54(1):31-8
   PubMed Web of Science ®Google Scholar
• Chua SL, Rosenthal MA, Wong SS, Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol 2004;6(1):38-43
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26(34):5610-17
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28(17):2817-23
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Giglio P, Groves MD, Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 2008;10(2):216-22
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Basso U, Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004;22(23):4779-86
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Cao Y, Marcello JE, Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26(2):271-8
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Eriksen JG, Broholm H, Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010;118(8):585-94
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R, Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 2010;99(2):237-42
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005;(7):369
   Google Scholar
• Xu T, Chen J, Lu Y, Wolff JE. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 2010;10:252
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-80
   PubMed Web of Science ®Google Scholar
• Finn MA, Blumenthal DT, Salzman KL, Jensen RL. Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 2007;67(3):246-50; discussion 250
   PubMedGoogle Scholar
• Ulmer S, Braga TA, Barker FG, Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006;67(9):1668-70
   PubMed Web of Science ®Google Scholar
• Kumar AJ, Leeds NE, Fuller GN, Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217(2):377-84
   PubMed Web of Science ®Google Scholar
• Henegar MM, Moran CJ, Silbergeld DL. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 1996;84(2):174-9
   PubMed Web of Science ®Google Scholar
• Taal W, Brandsma D, de Bruin HG, Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-10
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ, Chalmers L, Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82(1):81-3
   PubMed Web of Science ®Google Scholar
• Brandsma D, Stalpers L, Taal W, Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5):453-61
   PubMed Web of Science ®Google Scholar
• de Wit MCY, de Bruin HG, Eijkenboom W, Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63(3):535-7
   PubMed Web of Science ®Google Scholar
• Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008;29(3):419-24
   PubMed Web of Science ®Google Scholar
• Sorensen AG, Batchelor TT, Wen PY, Response criteria for glioma. Nat Clin Pract Oncol 2008;5(11):634-44
   PubMedGoogle Scholar
• van den Bent MJ, Vogelbaum MA, Wen PY, End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009;27(18):2905-8
   PubMed Web of Science ®Google Scholar
• Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15(14):4589-99
   PubMed Web of Science ®Google Scholar
• Polley MYC, Lamborn KR, Chang SM, Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 2010;12(3):274-82
   PubMed Web of Science ®Google Scholar
• Meyers CA, Boake С. Neurobehavioral disorders in brain tumor pa- tients: rehabilitation strategics. Cancer Bull 1993;45:362-4
   Google Scholar
• Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004;3(3):159-68
   PubMed Web of Science ®Google Scholar
• Bosma I, Vos MJ, Heimans JJ, The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol 2007;9(1):53-62
   PubMed Web of Science ®Google Scholar
• Meyers CA, Scheibel RS. Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park) 1990;4(7):115-22; discussion 122, 126
   PubMedGoogle Scholar
• Meyers CA. Deficits in brain-tumor patients: effects of location, chronicity and treatment. Cancer Bull 1986;38:20-32
   Google Scholar
• Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 1999;113(3):420-30
   PubMed Web of Science ®Google Scholar
• Young AH, Sahakian BJ, Robbins TW, Cowen PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology 1999;145(3):260-6
   PubMed Web of Science ®Google Scholar
• de Vries MAG, van Litsenburg RRL, Huisman J, Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study. Health Qual Life Outcomes 2008;6:103
   PubMed Web of Science ®Google Scholar
• Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 2002;10(4):322-8
   PubMed Web of Science ®Google Scholar
• Sturdza A, Millar BA, Bana N, The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008;16(9):1041-8
   PubMed Web of Science ®Google Scholar
• Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112(10):2267-73
   PubMed Web of Science ®Google Scholar
• Cloughesy T, Prados M, Wen P. A phase II, randomized non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan on 6 month progression free survival in recurrent, treatment refractory glioblastoma. Am J Clin Oncol 2008;26(15S):2010b
   Web of Science ®Google Scholar
• Desjardins A, Reardon DA, Herndon JE, Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14(21):7068-73
   PubMed Web of Science ®Google Scholar
• Guiu S, Taillibert S, Chinot O, Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 2008;164(6-7):588-94
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779-87
   PubMed Web of Science ®Google Scholar
• Raval S, Hwang S, Dorsett L. Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). Am J Clin Oncol 2007;25(18S):2078
   Google Scholar
• Nghiemphu PL, Liu W, Lee Y, Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72(14):1217-22
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30(9):907-11
   PubMed Web of Science ®Google Scholar
• Burger PC, Dubois PJ, Schold SC, Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983;58(2):159-69
   PubMed Web of Science ®Google Scholar
• Chang EL, Akyurek S, Avalos T, Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007;68(1):144-50
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284(5422):1994-8
   PubMed Web of Science ®Google Scholar
• Kunkel P, Ulbricht U, Bohlen P, Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61(18):6624-8
   PubMed Web of Science ®Google Scholar
• de Groot JF, Fuller G, Kumar AJ, Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12(3):233-42
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T, Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2(4):306-14
   PubMed Web of Science ®Google Scholar
• Lamszus K, Brockmann MA, Eckerich C, Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 2005;11(13):4934-40
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843-5
   PubMed Web of Science ®Google Scholar
• Hoper MM, Voelkel NF, Bates TO, Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997;17(6):748-56
   PubMed Web of Science ®Google Scholar
• Cheng T, Cao W, Wen R, Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 1998;39(3):581-91
   PubMed Web of Science ®Google Scholar
• Tuettenberg J, Grobholz R, Seiz M, Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 2009;135(9):1239-44
   PubMed Web of Science ®Google Scholar
• Milano MT, Okunieff P, Donatello RS, Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 2010;78(4):1147-55
   PubMed Web of Science ®Google Scholar
• Platten M, Dorner N, Hofer S. Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: a matched-pair study. J Natl Cancer Inst 2010;25(15S): abstract 2064
   Google Scholar
• Iwamoto FM, Abrey LE, Beal K, Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73(15):1200-6
   PubMed Web of Science ®Google Scholar
• Platten M, Dorner N, Hofer S, Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study. J Clin Oncol 2010;28(15s): abstract 2064
   Google Scholar
• Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101(2):319-23
   PubMed Web of Science ®Google Scholar